- Home
- ORKA vs AMSF Comparison
ORKA vs AMSF Comparison
Compare ORKA & AMSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORKA | AMSF |
|---|---|---|
| Founded | 2004 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Accident &Health Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 519.4M |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ORKA | AMSF |
|---|---|---|
| Price | $94.55 | $24.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $92.50 | $46.33 |
| AVG Volume (30 Days) | ★ 737.6K | 360.4K |
| Earning Date | 05-13-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 8.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $317,252,000.00 |
| Revenue This Year | N/A | $8.45 |
| Revenue Next Year | N/A | $6.03 |
| P/E Ratio | ★ N/A | $20.30 |
| Revenue Growth | N/A | ★ 2.66 |
| 52 Week Low | $14.89 | $24.11 |
| 52 Week High | $115.52 | $44.66 |
Technical Indicators
Market Signals| Indicator | ORKA | AMSF |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 26.04 |
| Support Level | $83.25 | $24.11 |
| Resistance Level | $97.02 | $34.15 |
| Average True Range (ATR) | 4.53 | 0.58 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 53.22 | 6.69 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.